PDF VI.2 Elements for a Public Summary VI.2.1 ... - Lægemiddelstyrelsen

- Upgrade of “Use in pregnant women” from missing information to important potential risk “Safety in pregnant women” - Rewording of “EPS including TD across all indications” to